<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365622</url>
  </required_header>
  <id_info>
    <org_study_id>70162</org_study_id>
    <nct_id>NCT03365622</nct_id>
  </id_info>
  <brief_title>Efficacy of IV Acetaminophen Versus Oral Acetaminophen</brief_title>
  <official_title>Randomized, Double-Blind Clinical Study Evaluating Efficacy of Intravenous Versus Enteric Acetaminophen in Donor Nephrectomy and Robot-Assisted, Laparoscopic Nephrectomy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether intravenous acetaminophen compared to enteric&#xD;
      acetaminophen offers increased efficacy in patients who are scheduled for laparoscopic donor&#xD;
      nephrectomy and for patients scheduled for robot-assisted, laparoscopic nephrectomy for renal&#xD;
      cancer at the University of Rochester Medical Center. The standard surgical and&#xD;
      post-operative care, including post-operative pain management will not be altered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare pain control for oral and intravenous acetaminophen for post-operative pain control. This will include opiates administered intra-operatively.</measure>
    <time_frame>20 to 24 hours post-operatively</time_frame>
    <description>Total opiate dose used from the study start (when the first dose of acetaminophen is administered in the pre-anesthesia holding area) to 24 hours post-operatively (in morphine equivalents).This will include opiates administered intra-operatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average surgical pain intensity</measure>
    <time_frame>20-24 hours post-operatively</time_frame>
    <description>Average surgical pain intensity on a 0-10 numeric rating scale (NRS) administered between 20 and 24 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Inspiratory capacity</measure>
    <time_frame>1-2 hours post-operatively</time_frame>
    <description>The inspiratory capacity will be presented as a percentage of the subject's baseline (pre-operative) inspiratory capacity.Inspiratory capacity is measured using a Voldyne 5000 incentive spirometer (Hudson RCI, Teleflex Medical). Inspiratory capacity will be recorded pre-operatively and at the time of pain assessments (1-2 hours and 20-24 hours post-operatively). Inspiratory capacity will recorded in milliliters to the nearest 250 cc mark on the incentive spirometer. Proper use of the incentive spirometer will be demonstrated to the patient in the pre-anesthesia holding area by a study investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean total opioid dose used in 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dynamic pain score during incentive spirometer use</measure>
    <time_frame>20-24 hours post-operatively</time_frame>
    <description>Pain intensity will be measured using a numeric rating scale of 0 to 10, with 10 being worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dynamic pain score during incentive spirometer use</measure>
    <time_frame>1-2 hours post-operatively</time_frame>
    <description>Pain intensity will be measured using a numeric rating scale of 0 to 10, with 10 being worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to first narcotic use</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean incidence of nausea post-operatively</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to discharge from post-anesthesia care unit</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to hospital discharge</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average surgical pain intensity on a 0-10 numeric rating scale (NRS)</measure>
    <time_frame>1-2 hours post-operatively</time_frame>
    <description>Pain intensity will be measured using a numeric rating scale of 0 to 10, with 10 being worse pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Nephrectomy</condition>
  <arm_group>
    <arm_group_label>IV acetaminophen and placebo pills</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo IV (normal saline) + oral acetaminophen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen</intervention_name>
    <description>Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.</description>
    <arm_group_label>IV acetaminophen and placebo pills</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours</description>
    <arm_group_label>placebo IV (normal saline) + oral acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.</description>
    <arm_group_label>placebo IV (normal saline) + oral acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours</description>
    <arm_group_label>IV acetaminophen and placebo pills</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years old&#xD;
&#xD;
          -  Be scheduled for donor nephrectomy or robot-assisted, laparoscopic nephrectomy for&#xD;
             cancer at University of Rochester Medical Center&#xD;
&#xD;
          -  Have cognitive ability to verbally rate their pain on the Numeric Rating Scale (NRS).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age younger than 18 years old or older than 90 years old&#xD;
&#xD;
          -  Pregnancy (Pre-operative pregnancy test is standard of care for all elective operating&#xD;
             room cases)&#xD;
&#xD;
          -  Weight less than 50 kg&#xD;
&#xD;
          -  Anticipated surgical case duration greater than 5 hours&#xD;
&#xD;
          -  Epidural use&#xD;
&#xD;
          -  History of known liver disease.&#xD;
&#xD;
          -  Patient unable to take enteral medications.&#xD;
&#xD;
          -  Be taking opioid medications chronically.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nancy Robertson, RN</last_name>
    <phone>585-275-1650</phone>
    <email>nancy_robertson@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammy Ortiz</last_name>
    <phone>585-273-2972</phone>
    <email>tammy_ortiz@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Robertson, RN</last_name>
      <phone>585-275-1650</phone>
      <email>nancy_robertson@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Ortiz</last_name>
      <phone>585-273-2972</phone>
      <email>tammy_ortiz@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Joseph W Dooley, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

